Ann: Viraleze shows antiviral efficacy in COVID-19 patients, page-70

It is simple guys and gals.

The Trial failed in under 45's and therefore as a whole.

No two ways about it.

My theory is that the trial failed to meet endpoints as a whole, and because of this SPL has taken their time to analyse the data and manipulate it in a way that suits them (splitting results into age cohorts).

I commend them for doing so, because that is a nice way of polishing the turd. BUT it does not change the FACT that the trial failed to meet its endpoints and therefore the product in UK will remain to be marketed as a cold and flu spray and not the COVID fighting nasal spray that all of us here want to be.